Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Maida Wong"'
Publikováno v:
Saturday, 15 June 2019.
Background: Gout is the most prevalent inflammatory arthritis globally. Despite treatment advances, it still has a significant effect on quality of life and healthcare costs. There have been inconsistent studies on administrative coding as an accurat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aaa90ba3cf4bfe933bdca8654516bcc9
https://doi.org/10.1136/annrheumdis-2019-eular.598
https://doi.org/10.1136/annrheumdis-2019-eular.598
Autor:
Maida Wong, Bevra H. Hahn
Publikováno v:
Abstracts.
Background In systemic lupus erythematosus (SLE), dysregulated production of autoantibodies is a consequence of disrupted T cell homeostasis. We have published that blockade of Programmed death-1 (PD-1), a negative regulator in T cells, limits helper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::baecbf402ee9e7e66d339c2c4d7fc4e6
https://doi.org/10.1136/lupus-2019-lsm.195
https://doi.org/10.1136/lupus-2019-lsm.195
Publikováno v:
Arthritis & Rheumatology. 66:674-685
Objective Lupus nephritis depends on autoantibody deposition and activation of multiple immune cell types that promote kidney inflammation, including lymphocytes and monocyte/macrophages. Laquinimod, currently in clinical trials for multiple sclerosi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f565e4a13eefa674e7320166fe16bf2
https://doi.org/10.1002/art.38259
https://doi.org/10.1002/art.38259
Publikováno v:
The Journal of Immunology. 190:5402-5410
Programmed death-1 (PD-1) usually acts as a negative signal for T cell activation, and its expression on CD8+Foxp3+ T cells is required for their suppressive capacity. In this study, we show that PD-1 signaling is required for the maintenance of func
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a82bbeb75ed87a14236b22f1a9e01849
https://doi.org/10.4049/jimmunol.1202382
https://doi.org/10.4049/jimmunol.1202382
Publikováno v:
The Journal of Immunology. 185:6563-6571
The programmed death-1 (PD-1)/programmed death-1 ligand 1 (PD-L1) pathway regulates both stimulatory and inhibitory signals. In some conditions, PD-1/PD-L1 inhibits T and B cell activation, induces anergy, and reduces cytotoxicity in CD8+ T cells. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f388f2785fe7273057668ed2efc9ec02
https://doi.org/10.4049/jimmunol.0903401
https://doi.org/10.4049/jimmunol.0903401
Publikováno v:
The Journal of Immunology. 178:7649-7657
Systemic lupus erythematosus is an autoimmune disease caused by autoantibodies, including IgG anti-DNA. New Zealand Black/New Zealand White F1 female mice, a model of spontaneous polygenic systemic lupus erythematosus, tolerized with an artificial pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3246c170e5641d88d1c410b25bcba631
https://doi.org/10.4049/jimmunol.178.12.7649
https://doi.org/10.4049/jimmunol.178.12.7649
Autor:
And C. S. Lau, Maida Wong
Publikováno v:
APLAR Journal of Rheumatology. 9:387-391
Systemic lupus erythematosus (SLE) has remained one of the most baffling autoimmune rheumatic diseases since it was described in the 19th century. It is a multisystemic, chronic condition that affects individuals with life-threatening irreversible en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c24433c0d3694a0b2a5938d55dad56ac
https://doi.org/10.1111/j.1479-8077.2006.00246.x
https://doi.org/10.1111/j.1479-8077.2006.00246.x
Publikováno v:
Arthritisrheumatology (Hoboken, N.J.). 66(3)
Lupus nephritis depends on autoantibody deposition and activation of multiple immune cell types that promote kidney inflammation, including lymphocytes and monocyte/macrophages. Laquinimod, currently in clinical trials for multiple sclerosis and lupu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d0d7afddf912cf158ee59f5c445384cf
https://pubmed.ncbi.nlm.nih.gov/24574228
https://pubmed.ncbi.nlm.nih.gov/24574228
Publikováno v:
Arthritis Research & Therapy
In 2012, recommended therapies for SLE include antimalarials, glucocorticoids, azathioprine, mycophenolate mofetil (or myfortic acid), cyclophosphamide, and other immunosuppressants. Belimumab has been added recently. Most are targeted toward adaptiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eb2c8602cf0106e56bc1b597975c414
https://doi.org/10.1186/ar3985
https://doi.org/10.1186/ar3985
Autor:
John B. Harley, Yu-Lung Lau, Fei Lan Liu, Yuanjia Tang, Betty P. Tsao, Ji Yih Chen, Deh Ming Chang, Aya Kawasaki, Yee Ling Wu, Kenneth M. Kaufman, Xiaoxia Qian, Jennifer M. Grossman, Shunle Chen, C. Yung Yu, Bevra H. Hahn, Yasushi Kawaguchi, Joel M. Guthridge, Qiong Fu, Rita M. Cantor, Zhao Jian, Yeong Wook Song, So Young Bang, Yun Deng, Yoshinari Takasaki, Naoyuki Tsuchiya, Wanling Yang, Hwee Siew Howe, Nan Shen, Hiroshi Hashimoto, Sang Cheol Bae, Mo Yin Mok, Takayuki Sumida, Maida Wong
Systemic lupus erythematosus (SLE) is a multisystem, autoimmune disease that predominantly affects women. Previous findings that duplicated Toll-like receptor 7 (Tlr7) promotes lupus-like disease in male BXSB mice prompted us to evaluate TLR7 in huma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8dc59c3a77351ad3be450bd5b3330aa
https://europepmc.org/articles/PMC2936646/
https://europepmc.org/articles/PMC2936646/
